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Welcome to the latest module 
in the Pharmacy Magazine Continuing 
Professional Development Programme.
   
 Journal-based educational programmes are 
an important means of keeping up to date 
with your clinical and professional 
knowledge. Completion of this module 
will contribute to the nine pieces of CPD 
that must currently be recorded each year. 
    
Before reading this module, test your existing 
understanding of the subject by completing 
the pre-test at pharmacymagazine.co.uk. 
Then, after studying the module in the 
magazine or online, work through the 
post-test on the website to check 
your answers. Record your 
learning using your personal 
Pharmacy Magazine 
online log.
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GOALS AND LEARNING OBJECTIVES 
This module will help you understand the changing 
healthcare and pharmacological needs of individuals 
diagnosed with mild cognitive impairment, which  
then leads to a formal diagnosis of dementia.  
You will be able to describe the difference 
between cognitive impairment in normal 
ageing and that in dementia, name the 
different types of dementia likely to be 
encountered in primary care 
and understand the 
pharmacological 
and non-
pharmacological 
treatment 
options for 
dementia. 
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You can complete this module online at pharmacymagazine.co.uk 
and record your learning outcomes and the impact on your practice in your own 
personal and confidential learning log 
KEY FACTS
850,000 people in the UK live with dementia, which is 
projected to rise to over 1 million by 2025
62 per cent of people with dementia are female, probably because life 
expectancy is higher in women and age is the biggest known risk factor 
for the disease
There is no cure for any form of dementia, except for the pseudodementias, 
which may respond to treatment
Risk reduction for dementia includes lowering modifiable cardio and 
cerebrovascular risk factors 
Early interventions include planning for the future in terms of advocacy and 
end-of-life care options  
Pharmacological treatment is multifactorial including pharmacological 
support of cognitive function and maintaining physical and mental  
health by inclusion in socially and mentally stimulating activities
Acetylcholinesterase inhibitors and memantine improve  
cognitive function
Future therapies will include monoclonal  
antibodies and small  
molecule treatments
ii CPD MARCH 2017 PHARMACY MAGAZINE                                                                                    THIS CPD MODULE PLUS PRE-TEST AND POST-TEST IS ONLINE AT PHARMACYMAGAZINE.CO.UK   
Introduction &        
module overview
This module introduces the concept of mild cognitive impairment (MCI), which may or may not be 
related to an individual having the underlying pathophysiology of Alzheimer’s disease (AD). For 
example, people can experience mild cognitive impairment as part of normal ageing, and as a result 
of a head injury (trauma, infection, surgery or stroke), misuse or inappropriate use of substances 
including medicines and alcohol, or metabolic disturbances involving glucose, calcium or sodium.
The differential diagnostic process is an important part of establishing the cause of the MCI and then 
signposting appropriately for treatment or symptom control.
Dementia prevention is now a public health issue that all healthcare professionals need to be aware 
of to best support their patients and local community.
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Cognitive impairment
Cognitive function is not just about memory, but includes language, 
visuospatial and perceptual ability, thinking and problem-solving, and 
personality. This means that any impairment may manifest as memory 
problems, but also problems in reading or speaking, difficulty in managing 
financial affairs or loss of interest in attending social activities, through to 
exhibiting signs of delusion or paranoia, or becoming agitated, anxious or angry. 
In normal ageing there are changes in our cognitive functioning: thinking and 
planning take longer; people may need to make lists to remember their daily 
activities or use diaries or planners; they may have trouble with word finding; 
for example, forgetting the names of actors in a film or a famous person (but 
remembering them later) or forgetting a particular word in the middle of a 
conversation. These are normal signs. It is only when they become sufficiently  
severe to interfere with a person’s ability to complete their usual daily activities  
that there is cause for concern.
Mild cognitive impairment due to Alzheimer’s disease
A diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) 
is made according to consensus guidelines. There are two main forms: amnestic 
and non-amnestic MCI. People with the former diagnosis mainly exhibit problems 
with their episodic memory (they cannot learn or retain new information) on initial 
diagnosis and 50 per cent will progress to a formal diagnosis of AD. Currently, 
there is no ability to predict those most likely to progress to this stage and no 
pharmacological treatments to halt this process. 
This impairment of episodic memory is not normal for age and is generally 
associated with other symptoms of cognitive impairment sufficient to interfere 
with normal daily activities and personal relationships. It is important to note that 
there are other possible causes of cognitive impairment, including head trauma, 
substance misuse (including alcohol and medication) and metabolic disturbance.  
Dementia
Dementia has been defined as “a syndrome consisting of progressive impairment 
in two or more areas of cognition, sufficient to interfere with work, social function 
or relationships”.
In 2015, there were an estimated 856,700 people with dementia in the UK. 
Established prevalence rates link the risk of dementia with increasing age, rising 
from one in 688 people under 65 years, to one in 14 people over 65 years, one in 
six over 80 years and one in three over 90 years. 
Recent research suggests the proportion of people living with dementia has 
decreased by 20 per cent over the past two decades, linked mainly to reduction  
in male smoking, leading healthier lives and a reduction of cardiovascular risks. 
General symptoms
Dementia is neurodegenerative, so there is gradual onset, often noticed at times  
of stress or change (e.g. when admitted to hospital with an infection or when  
there is a change in environment). The presentation of symptoms is influenced by  
pre-morbid personality. Early symptoms include:
Table 1: Ten warning signs for Alzheimer’s disease
Warning sign of Alzheimer’s disease
Memory loss that disrupts daily life 
Forgetting recently learned or unable to learn 
new information. Repeatedly asking for the 
same information
Challenges in planning or problem solving 
Find it a challenge to manage finance, follow a 
plan and take longer to do things
Difficulty completing familiar tasks at home, 
work or leisure 
Getting lost driving to familiar places, 
struggles with project management at work or 
remembering the rules of a favourite game
Confusion with time or place
Losing track of dates, seasons or passage of 
time. May forget where they are or how they 
got there
Trouble understanding visual images and 
spatial relationships
This is an early sign and includes trouble 
reading, judging distance and determining 
colour or contrast. This may also present 
as hallucinations. In terms of perception, a 
sufferer may pass a mirror and think someone 
else is in the room
New problems with communication
Difficulty following or maintaining 
conversation; problems finding or using the 
correct word
Misplacing items
May put items in unusual places (spectacles in 
the fridge) and may accuse people of stealing 
them. Cannot retrace steps to find the item
Impaired or reduced judgement
Make poor decisions often involving money 
or large donations to telemarketeers, for 
example. Less attention to personal grooming
Withdrawal from work or social activities
May have trouble keeping up with favourite 
activities or remembering how to do them. 
May withdraw socially because of these 
changes
Changes in mood or personality
May become confused, suspicious, depressed, 
fearful, anxious or even delusional. May be 
upset easily doing routine tasks when out of 
their comfort zone
Signs of normal ageing
Sometimes forgetting 
names or appointments but 
remembering them later
Making occasional errors 
when balancing a cheque 
book or household accounts
Occasionally needing help 
with settings on microwave 
or television
Getting confused about the 
day of the week but working 
it out later
Vision changes related to 
cataracts
Sometimes having trouble 
finding the right word
Occasionally misplacing 
things like spectacles or  
TV remote control
Making a bad decision 
occasionally
Sometimes feeling weary 
of work, family and social 
obligations
Developing a specific way 
of doing things and being 
irritable when a routine is 
disrupted
Adapted from Alzheimer’s Association, 2009  alz.org/alzheimers_disease_10_signs_of_alzheimers.asp 
Would you be able to create a list of referral or signposting links 
that are local to you for people with dementia and their families? 
• The Alzheimer’s Society website (alzheimers.org.uk) or Dementia 
Action Alliance (dementiaaction.org.uk/resources) provide useful 
resources for healthcare professionals and the public.
Reflection exercise 1
•  Memory loss, especially for recent events
•  Difficulties with learning and/or retaining new information 
•  Being more repetitive or misplacing objects (e.g. car keys or spectacles)
•  Having trouble with complex tasks such as cooking, driving or dealing with 
finances
•  Reduced ability to reason and problem-solve
•  Impairment of spatial and visuospatial awareness (e.g. bumping into objects; 
getting lost in a familiar place)
•  Language problems: inability to find the right word or difficulty following 
conversations
•  Behavioural changes: more irritable, passive, withdrawn or suspicious.
Diagnosis
There is no definitive laboratory or tissue marker for the diagnosis of any dementia, 
so diagnosis is one of exclusion requiring a full medical history and multi-faceted 
assessment to exclude pseudodementias (which account for about 1 per cent of all 
dementias) as these are the only potentially reversible types of the disease.
Diagnostic assessments include laboratory screening of blood indices and 
imaging techniques such as computed tomography (CT) scans to exclude space 
occupying lesions, and magnetic resonance imaging (MRI) and positron emission 
tomography (PET) scans to establish where brain loss is occurring and its severity. 
Psychological scales assess disease severity, cognitive functioning, activities of 
daily living and problem-solving. A practical toolkit for healthcare professionals 
for assessing cognitive impairment is available at alzheimers.org.uk/site/scripts/
documents_info.php?documentID=2159.
Dependent on findings from imaging, blood markers and, where appropriate, 
genetic testing, a probable diagnosis can be made. In the United Kingdom, AD 
accounts for 62 per cent of all cases, vascular dementia (VaD) 17 per cent, mixed 
AD & VaD 10 per cent, dementia with Lewy bodies 4 per cent and frontotemporal 
dementia 2 per cent. Rarer dementias (including Parkinson’s disease dementia, 
prion disease and alcohol-related dementia) account for 5 per cent.
Signs and symptoms 
Disease progression varies considerably, but broadly falls into four stages:
Early stage: This is often misattributed to stress, bereavement or normal ageing. 
Signs and symptoms include: 
• Mood changes
• Loss of short-term memory
• Confusion, poor judgement, unwillingness to make decisions 
• Anxiety, agitation or distress over perceived changes 
• Inability to manage everyday tasks.
Moderate stage: This is associated with needing more support for tasks of every- 
day living, including reminders to eat, wash, dress and use the lavatory. People 
are increasingly forgetful and may fail to recognise others. Distress, aggression 
and anger are common, perhaps due to frustration. Risks include wandering and 
getting lost, leaving taps running or the gas on, inappropriate behaviour, dressing 
incorrectly, loss of day-night cycle and hallucinations.
Late stage: This includes an inability to recognise familiar objects, surroundings 
or people – although there can be some flashes of recognition. Increasing physical 
frailty means people may start to shuffle or walk unsteadily, eventually 
becoming confined to bed or a chair. Difficulty eating and sometimes 
swallowing, weight loss, double incontinence and gradual loss of speech  
all occur in this late stage.
End-of-life stage: Requires good palliative care services.
Alzheimer’s disease
Diagnosis is by clinical and neuropsychological examination and the presence of 
deficits in at least two areas of cognition with progressive worsening of memory. 
There is no disturbance of consciousness and an absence of other disorders to 
account for dementia. Pathophysiological features include neurofibrillary tangles 
and amyloid plaque deposition. 
AD is most likely the sum of external factors (an environmental trigger) plus 
inherent host factors (genetic predisposition). However, genetic predisposition only 
accounts for about 5 per cent of all cases and influences, whether AD occurs as 
early onset (<55 years) or late onset (>65 years). Increasingly, evidence suggests 
that AD is related to lifestyle choices.
Associated risk and protective factors include:
Increasing age: Age reflects the passage of time, so there is more time for genes 
to express themselves. This leads to an increasing inability to repair cell damage 
and/or more time to be exposed to environmental agents that may be involved in 
the onset of AD
Gender: Studies suggest a slightly higher incidence in women than men, but this 
may be because women live longer
Genetic predisposition: Specific genes link age at onset, duration and disease 
severity. Genetic risk is an autosomal dominant inheritance. Each person with 
an affected gene had one parent with the gene, and the offspring of a person 
with an affected gene has a 50:50 chance of inheriting the gene. It does not skip 
generations and men and women are equally affected
Head injury: Deposition of amyloid plaques triggering neurodegeneration
Other risk factors: Epilepsy, herpes zoster/simplex virus, alcohol, smoking, 
cardiovascular and cerebrovascular disease, older maternal age.
Protective factors include:
Education: Maintaining intellectual functioning and exercise – a healthy 
cardiovascular system equates to a healthy cerebrovascular system.
Vascular dementia 
Vascular dementia (VaD) refers to a group of syndromes where dementia is 
precipitated by ischaemia or haemorrhage secondary to cerebrovascular disease. 
VaD usually has sudden onset and then follows a step-wise process (periods of 
stability followed by sudden decline) as the result of cerebral ischaemic events. 
There are focal neurological signs and symptoms, and relative preservation of 
personality. Often there is nocturnal confusion, the presence of depression and 
patchy cognitive impairment.
VaD is potentially preventable by improving cerebral perfusion and preventing 
ischaemia by the use of antiplatelets, warfarin or novel anticoagulants, and by 
controlling underlying hypertension, cardiovascular disease and/or diabetes. 
Statins have a role in lipid regulation, which may contribute to the pathogenesis  
of dementia – so they may have a role in reducing incidence of VaD.
Dementia with Lewy bodies 
Dementia with Lewy bodies (DLB) typically follows a progressive, fluctuating 
course and is delirium-like, with fluctuating periods of confusion and variations 
in attention and alertness. Visual hallucinations are common, as are Parkinsonian 
features such as rigidity and bradykinesia with repeated falls. Pathophysiological 
features include Lewy bodies and the widespread reduction of choline acetyl-
transferase in the neocortex and dopamine in the caudate nucleus. 
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How could you support the carer of a person with dementia 
to ensure medication is being given appropriately? Would you 
recommend any memory aides and, if so, which ones and why? 
Reflection exercise 2
People with 
DLB exhibit 
extreme sensitivity to 
antipsychotics, leading to a 
three-fold increase in mortality 
as they exacerbate both motor and 
cognitive disability. These medications 
should be avoided completely if possible. 
If there is an absolute need to use them, 
they should be started at one-quarter of the 
usual dose, monitored carefully and withdrawn as 
soon as possible.
Lewy bodies are also found in the brains of people 
with Parkinson’s disease (PD). Eighty per cent of people 
with PD will develop PD dementia over time and exhibit the 
same sensitivity to antipsychotics.
Behavioural and psychological symptoms  
of dementia 
Behaviour changes are in response to disease progression and are 
associated with the death of brain cells, as well as the frustration 
at not being able to communicate or remember effectively. 
Behavioural and psychological symptoms of dementia 
(BPSD) occur in 95 per cent of people with dementia and 
include the expression of delusions, hallucinations, agitation 
or aggression, depression, anxiety, elation or euphoria, 
apathy or indifference, disinhibition, irritation or lability, 
aberrant motor behaviour (wandering), night-time behaviour 
(sundowning), or a change in eating habits.
Symptom management 
People who receive a diagnosis of mild cognitive impairment 
due to AD (sometimes known as amnestic MCI) will need 
early support and signposting to information resources for 
dementia care and also legal guidance; for example, in terms  
of setting up advance directives and power of attorney. 
Evidence suggests that reducing and/or treating cardiovascular 
and cerebrovascular risks appropriately, eating healthily, exercising 
regularly, being involved in mentally and socially stimulating activities, 
reducing stress and getting sufficient sleep, all reduce the risk of and/
or delay the onset of dementia. Evidence-based activities include singing, 
Pharmacy Magazine’s CPD modules are available on Cegedim Rx’s  
PMR systems, Pharmacy Manager and Nexphase. 
Just click on the ‘Professional Information & Articles’ button  
within  Pharmacy KnowledgeBase and search by therapy area.    
Please call the Cegedim Rx helpdesk on 0844 630 2002    
for further information.
John Warner is 58 and retired six months ago from his job as a university 
lecturer. Although you have dispensed prescriptions for his high blood 
pressure, you have not met him before. He comes into the pharmacy with 
his wife, who asks for a word in private. Mr Warner seems pleasant and 
sociable but you notice his shirt is buttoned incorrectly and his socks do 
not match. He says he feels completely fine, just a little tired and more 
forgetful than usual. At this, his wife gets rather upset and says that he 
is not just forgetful anymore, but a danger to himself. He took their two 
dogs for a walk yesterday to the local park but could not remember his 
way home. When you ask Mr Warner about this he admits it has been 
getting worse for some years and was one of the reasons he took 
early retirement. He had put this down to work-related stress 
but admits things are getting worse, not better. He wants 
to know if this is just old age or whether he might 
have something worse, like dementia. What do you 
suggest the signs and symptoms that Mr Warner 
has been displaying are likely to be?
a. Early onset dementia
b. Worsening memory due to old age
c. Mild cognitive impairment 
d. Early signs of a neuro- 
degenerative process 
such as dementia
Learning scenario 1 Learning scenario 2 
Mr Barnett rings you one morning in a bit of a state. His wife has  
fallen again, hit her head and it has been bleeding. After ensuring  
that Mrs Barnett is conscious and not confused, you ask him to tell 
you what has happened over the past week or so that may have been  
causing the falls. You remember that Mrs Barnett was started on 
donepezil 5mg about two months ago and was also taking digoxin and 
aspirin for atrial fibrillation. Mr Barnett says that nothing in their 
routine had really changed, except last week the specialist increased 
the donepezil dose to 10mg. Mrs Barnett had not fallen before that, 
he says, but as the medication was still the same, how could it be 
involved? What would you advise Mr Barnett?
a. Continue as normal and see if the falls stop
b.  If the falls are only happening during the day, change to a  
night-time dose
c.  Contact the GP or specialist immediately as the increased dose may 
be causing a slowed heart rate, which is leading to the falls 
d.  Contact the prescriber and ask that his wife be switched to  
memantine
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learning a new language, dancing, gardening, group exercise (walking, swimming, 
playing table tennis), completing jigsaws, crosswords, mind exercises and also 
listening to music. 
Therapeutic treatment of the dementias
NICE Technology Appraisal (TA) 217 states that three licensed acetylcholinesterase 
inhibitors (AChEIs) – donepezil, rivastigmine and galantamine – are recommended 
for mild and moderate AD, and the NMDA-receptor antagonist memantine for 
managing moderate or severe AD or for people who cannot tolerate AChEIs. 
Acetylcholinesterase inhibitors 
These may improve memory significantly but benefits in social relationships, mood, 
behaviour and activities of daily living outweigh this. Rivastigmine is also licensed 
for the symptomatic treatment of mild to moderately severe Parkinson’s disease 
dementia. AChEIs are also an option for people with a mixed diagnosis including 
AD. There are no licensed treatments for any other of the dementias, although  
HIV-related dementia has been greatly reduced by the use of highly active 
antiretroviral therapy (HAART).
Side-effects are predominantly cholinergic and include diarrhoea, nausea, 
possible vomiting and nasal rhinitis. Others include muscle cramps, fatigue, 
insomnia and dizziness. AChEls may cause syncope and any falls or faints should 
be referred immediately.
It is important to note that an individual may experience relatively severe adverse 
effects with one agent, but not another. Non-response with one does not mean 
non-response with all, and an alternative should be tried.
The decision when to stop an AChEI is complex, as even when it seems there 
is no response, there may be a rapid deterioration in mood and behaviour on 
discontinuation. In these instances, clinical advice is to restart as soon as possible. 
In end-stage care, when the process is one of palliation, all medication should 
be reviewed and withdrawn as appropriate.
Memantine 
Studies demonstrate significant improvement in cognition, activities of daily living 
and global outcomes, and a reduction in agitation with memantine. Common 
adverse effects include constipation, hypotension, confusion, dizziness, headache 
and tiredness. If tiredness is present, evening dosing could be considered to 
promote sleep. 
Other treatments
People with dementia and their families may turn to OTC and herbal supplements 
to try and prevent and/or delay the onset of dementia. Popular remedies include 
ginkgo biloba, which increases cerebral blood supply and reduces blood viscosity. 
Evidence for improvement is inconsistent and it is unknown whether long-term 
use delays or prevents onset of dementia, but it is safe to use and well-tolerated. 
There is a theoretical interaction with aspirin or warfarin, and the prescriber 
should be consulted before use in these circumstances. 
Other vitamin or mineral supplements, such as folic acid, vitamin B12 or iron 
are only effective if there is a deficit. (Deficits are linked to impaired cognition and 
often referred to as a pseudodementia.) Older people may not eat sufficient fresh 
green vegetables or dietary protein to sustain normal levels and active transport 
mechanisms for B12 absorption may be impaired. 
Non-pharmacological approaches 
Educational programmes for carers (family and support organisations) using 
behavioural interventions are more effective than most pharmacological 
treatments in dealing with behavioural and psychological symptoms of dementia.  
These include distraction, reality orientation, occupational activities, reminiscence, 
sensory stimulation, social interaction, as well as exploring any possible underlying 
causes, such as pain, anxiety, depression, or a recent change or upsetting event.
The management of sundowning (where people can lose a sense of whether it 
is day or night) is achieved by minimising catnapping during the day (to increase 
sleep at night), regular exercise, and establishing a day and night routine. Use 
of bright light (Lux) in the morning can reduce the incidence of agitation in the 
evening.
Future treatments
Current clinical trials include the re-positioning of licensed medicines, such as 
antihypertensives (calcium channel blockers) or antidiabetic agents (pioglitazone), 
as well as exploring the effect of insulin resistance on brain function. 
    Potential treatments aimed at the prevention and treatment of established 
dementias include monoclonal antibodies, which aim to reduce cerebral amyloid 
deposition, and small molecules, which reduce amyloid-beta production, tau 
aggregation or neuroinflammation. 
• References available from the Editor on request
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a.  Early onset dementia  
INCORRECT. Early onset dementia is diagnosed in people who are under  
55 years of age.
 b.   Worsening memory due to old age 
INCORRECT. Relatively speaking, Mr Warner is still quite young. In addition, 
in old age, visuospatial awareness (which enables a person to find their way 
home) is generally intact.
 c.   Mild cognitive impairment  
INCORRECT. There are defects in episodic memory in mild cognitive 
impairment, but getting lost in familiar places implies more serious 
cognitive difficulties. 
 d.  Early signs of a neurodegenerative process such as dementia 
CORRECT. The behaviour Mr and Mrs Warner describe is related to the short-
term memory impairment and changes in visuospatial skills that are seen in 
the early stages of dementia.
Answers: learning scenario 1
a.  Continue as normal and see if the falls stop 
INCORRECT. Any fall needs to be investigated as a priority due to the risk of 
further head trauma or possible fractures.
b.  If the falls are only happening during the day, change to a night-time dose 
INCORRECT. This is not a solution. Mrs Barnett could still fall if she gets up 
in the night.
c.  Contact the GP or specialist immediately as the increased donepezil dose 
may be causing a slowed heart rate, which is leading to the falls  
CORRECT. Her GP should know about the falls as these may be a result of 
bradycardia from the donepezil and digoxin causing syncope, which leads  
to collapse and falls.
d.  Contact the prescriber and ask that Mrs Barnett is switched to memantine 
INCORRECT. Memantine is not appropriate for mild AD and is only 
recommended for moderate AD if there is intolerance to all AChEIs.
Answers: learning scenario 2
Now test your learning online
Complete the pre- and post-test for this module free of charge at  
pharmacymagazine.co.uk – you need to register first – and record  
your learning outcomes in your personal learning log.
Register at: www.pharmacymagazine.co.uk
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